Literature DB >> 23251744

Current and emerging therapies for the management of functional gastrointestinal disorders.

Orla F Craig1, Eamonn M M Quigley.   

Abstract

The functional gastrointestinal disorders are common disorders that are associated with significant quality-of-life impairment and considerable economic burden on the healthcare system. They are frequently associated with a comorbid psychiatric condition; this, together with a striking lack of effective pharmacological therapies, means they represent a considerable therapeutic challenge to the treating physician. In this overview, we examine the evidence to support the use of agents currently used in the management of the more common functional gastrointestinal disorders and review emerging therapies.

Entities:  

Keywords:  antibiotics; antidepressants; cognitive behavioural therapy; functional dyspepsia; functional gastrointestinal disorders; functional heartburn; irritable bowel syndrome; probiotics; serotonin

Year:  2011        PMID： 23251744      PMCID： PMC3513878          DOI： 10.1177/2040622310389507

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


  110 in total

1.  Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite.

Authors:  Takashi Akamizu; Hiroshi Iwakura; Hiroyuki Ariyasu; Hiroshi Hosoda; Toshinori Murayama; Masayuki Yokode; Satoshi Teramukai; Hiroshi Seno; Tsutomu Chiba; Shunichi Noma; Yoshikatsu Nakai; Mikihiko Fukunaga; Yoshihide Nakai; Kenji Kangawa
Journal:  Eur J Endocrinol       Date:  2008-04       Impact factor: 6.664

2.  Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome.

Authors:  B J Dolin
Journal:  Methods Find Exp Clin Pharmacol       Date:  2009-12

Review 3.  Irritable bowel syndrome: role of food in pathogenesis and management.

Authors:  Ashraf Morcos; Ted Dinan; Eamonn M M Quigley
Journal:  J Dig Dis       Date:  2009-11       Impact factor: 2.325

Review 4.  Review article: new receptor targets for medical therapy in irritable bowel syndrome.

Authors:  M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2010-01       Impact factor: 8.171

5.  A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.

Authors:  Kei Matsueda; Shigeru Harasawa; Michio Hongo; Nobuo Hiwatashi; Daisuke Sasaki
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

6.  Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials.

Authors:  Nimish Vakil; Loren Laine; Nicholas J Talley; Salam F Zakko; Jan Tack; William D Chey; Jeffrey Kralstein; David L Earnest; Gregory Ligozio; Marielle Cohard-Radice
Journal:  Am J Gastroenterol       Date:  2008-07-04       Impact factor: 10.864

Review 7.  Whither dyspepsia? A historical perspective of functional dyspepsia, and concepts of pathogenesis and therapy in 2009.

Authors:  Nicholas J Talley; Rok Seon Choung
Journal:  J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 4.029

8.  Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy.

Authors:  George Karamanolis; Tim Vanuytsel; Daniel Sifrim; Raf Bisschops; Joris Arts; Philip Caenepeel; Dominiek Dewulf; Jan Tack
Journal:  Dig Dis Sci       Date:  2008-03-06       Impact factor: 3.199

9.  Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

Authors:  D A Drossman; W D Chey; J F Johanson; R Fass; C Scott; R Panas; R Ueno
Journal:  Aliment Pharmacol Ther       Date:  2008-11-04       Impact factor: 8.171

10.  The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria.

Authors:  Anjiang Wang; XianHua Liao; LiShou Xiong; Sui Peng; YingLian Xiao; SiChun Liu; PinJin Hu; MinHu Chen
Journal:  BMC Gastroenterol       Date:  2008-09-23       Impact factor: 3.067
View more
  5 in total

1.  Open channels for functional bowel disorders: guanylate cyclase C agonists in IBS and CC.

Authors:  Eamonn M M Quigley
Journal:  Dig Dis Sci       Date:  2013-09       Impact factor: 3.199

Review 2.  Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.

Authors:  Gerald Holtmann; Dietmar Schrenk; Ahmed Madisch; Hans D Allescher; Gudrun Ulrich-Merzenich; Fermin Mearin; Dominique Larrey; Peter Malfertheiner
Journal:  Dig Dis       Date:  2019-11-26       Impact factor: 2.404

3.  Prevalence of Helicobacter Pylori Infection and Stress, Anxiety or Depression in Functional Dyspepsia and Outcome after Appropriate Intervention.

Authors:  Kirti Katherine Kabeer; Nilakanthan Ananthakrishnan; Chetan Anand; Sivaprakash Balasundaram
Journal:  J Clin Diagn Res       Date:  2017-08-01

4.  Underlying mechanism of aconitum lizhong acting on experimental hypothermia with indigestion in rats: role of ghrelin.

Authors:  Xin Zhao; Yong Wang; Shijun Yang; Wentong Zhang; Chengzhe Zu; Taotao Zhang; Binghua Tang; Baochun Zhang; Guozhang Li; Bo Deng; Dayong Cai
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-31       Impact factor: 2.629

5.  Efficacy of prebiotics and probiotics for functional dyspepsia: A systematic review and meta-analysis.

Authors:  Jiaqi Zhang; Hao Meng Wu; Xue Wang; Jingyi Xie; Xia Li; Jinxin Ma; Fengyun Wang; Xudong Tang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.